Background
==========

Chromatin remodeling is the dynamic modification of chromatin architecture essential to many biological processes, including cell division, gene expression, and DNA replication, packaging and repair \[[@B1]-[@B3]\]. The chromodomain helicase DNA binding (CHD) proteins belong to the SNF2-related superfamily of ATPases, which use the energy from ATP hydrolysis to change nucleosome positioning, composition and chromatin structure. The CHD family is defined by the presence of tandem chromo (chromatin organisation modifier) domains in the N-terminal region and a central SNF2-related helicase/ATPase domain \[[@B4]\]. The latter is the catalytic core mediating chromatin alteration. Members of the CHD family are divided into three subfamilies according to their additional structural motifs. (1) CHD1 and CHD2 possess a C-terminal DNA binding domain recognizing AT-rich DNA motifs. (2) CHD3 and CHD4 contain a pair of plant homeodomain zinc finger domains in their N-terminal regions and lack a DNA binding domain. (3) CHD5 to CHD9, which contain diverse additional functional domains such as the BRK (Brahma and Kismet) domain, SANT-like (switching-defective protein 3, adaptor 2, nuclear receptor corepressor, transcription factor IIIB) domain, CR domain and DNA binding domain \[[@B1],[@B5]\].

As CHD proteins play pivotal roles in modulating chromatin structure and are involved in processes such as gene activation and repression, DNA recombination and repair, cell-cycle regulation, development and cell differentiation, dysregulation of these proteins may have adverse effects on human development. Heterozygous mutations of the *CHD7* gene are known to cause the multisystem abnormalities associated with autosomal dominant CHARGE syndrome (coloboma, heart anomaly, choanal atresia, retardation, genital and ear anomalies) \[OMIM:214800\]. Characteristic anomalies include ocular coloboma, choanal atresia, cranial nerve defects, distinctive external and inner ear abnormalities, hearing loss, cardiovascular malformations, intellectual disability (ID), urogenital anomalies and growth retardation. More recently, exome sequencing studies have shown loss of function mutations affecting one allele of *CHD8* to be associated with autism spectrum disorder (ASD) \[[@B6]-[@B8]\].

There is emerging evidence showing *CHD2* haploinsufficiency is associated with neurodevelopmental abnormalities. Deletions affecting this gene are very rare, and, so far, there is only one case report of a child with global developmental delay, epilepsy and ASD who was found to have a *de novo* deletion encompassing the *RGMA* and *CHD2* genes \[[@B9]\]. However, because of the importance of *RGMA* in central nervous system axonal growth, haploinsufficiency of this gene was thought to be a good candidate to explain the patient's developmental delay and seizures. A deletion affecting *CHD2* was also reported in the supplemental data derived from genomic microarray analysis of 996 patients ascertained to have ASD \[[@B10]\]. This deletion involves *CHD2*, but not *RGMA*, and the patient was reported to have ASD and mild ID with no history of seizures or language delay. Recent studies have implicated *de novo* intragenic sequence mutations in *CHD2* in individuals with ID and a range of epileptic encephalopathies \[[@B11]-[@B13]\]. Although there is increasing evidence suggesting that mutations in *CHD2* contribute to a broad spectrum of neurodevelopmental disorders, a description of the full phenotypic spectrum is lacking.

In order to investigate the role of *CHD2* haploinsufficiency in neurodevelopmental disorders, we describe the first series of patients with deletions affecting *CHD2* from among a cohort of 42,313 patients broadly ascertained by clinical genetics laboratories to have developmental delay, intellectual disability, multiple congenital anomalies and/or ASD. We also present a review of the literature to correlate our patients' phenotypes with those previously reported with deletions and loss-of-function sequence mutations affecting this gene.

Methods
=======

We conducted a multicentre study of retrospective genomic copy number variation (CNV) data from six genetic diagnostics laboratories (see Additional file [1](#S1){ref-type="supplementary-material"}: Table S1), to collect phenotypic information from patients with deletions affecting *CHD2*. For all patients, phenotypic information was collected from genetics clinic assessments and medical chart reviews. This study is compliant with the research ethics boards of each participating institution. Signed informed consent was obtained from all study participants or their legal representatives. DNA extracted from uncultured cells, typically from peripheral blood lymphocytes, was used to perform genomic CNV analysis in all participating laboratories. Microarray experiments were performed according to the manufacturer's instructions. As described in Table S1, the microarray platforms used at each of the six diagnostic centres were oligonucleotide array--based. Deletions were confirmed, and parental follow-up studies were performed with multiplex ligation-dependent probe amplification (MLPA), array comparative genomics hybridization (aCGH) or fluorescence *in situ* hybridization (FISH) analysis. FISH analysis was performed using fosmid G248P83477D10 or CTD-2314 N10 bacterial artificial chromosome. We investigated the frequency of deletions affecting *CHD2* in high-resolution CNV data from among 13 control cohorts comprising a total of 26,826 individuals \[[@B10],[@B14]-[@B26]\].

Results
=======

We reviewed genomic CNV data from six genetic diagnostics laboratories that perform microarray analysis for patients broadly ascertained to have delayed developmental milestones in motor, speech and/or cognition skills (developmental delay); diagnosis of global developmental delay or ID, multiple congenital anomalies; and/or ASD. We identified four deletions affecting *CHD2* exonic sequences from a total of 42,313 patients analyzed. The deletions ranged in size from approximately 78 kb to 237 kb, with only one case also involving the *RGMA* gene, and all were found to be *de novo* (Figure [1](#F1){ref-type="fig"}). No other clinically significant CNVs were found in these patients. The clinical findings in these patients included developmental delay, learning difficulties or ID in all four patients, as well as seizures in three patients (Table [1](#T1){ref-type="table"}). The dysmorphic features observed in each of these patients are described in turn in the subsections below. However, no characteristic facial gestalt was found. Brain magnetic resonance imaging (MRI) did not reveal any malformations in our patients. Analysis of data derived from 26,826 individuals from population-based control cohorts evaluated by high-resolution CNV analysis did not show deletions affecting exonic sequences of *CHD2*, confirming the extreme rarity of this deletion in the general population (see Additional file [1](#S1){ref-type="supplementary-material"}: Table S2).

![Summary of deletions observed in our patients and reported in the literature.](1866-1955-6-9-1){#F1}

###### 

**Clinical characteristics of patients with*CHD2*deletions**^**a**^

  **Characteristics**                                 **Patient 1**                                 **Patient 2**                                 **Patient 3**                                                             **Patient 4**                                  **Pinto*et al*.**\[[@B10]\]                           **Capelli*et al*.**\[[@B9]\]
  --------------------------------------------------- --------------------------------------------- --------------------------------------------- ------------------------------------------------------------------------- ---------------------------------------------- ----------------------------------------------------- -------------------------------------------
  Gender                                              F                                             F                                             F                                                                         F                                              M                                                     F
  Age (yr)                                            11                                            9                                             6                                                                         16                                             Not specified                                         6
  Chr15 deletion \[hg19\] start--end (bp)             93,324,047 to 93,515,100                      93,286,333 to 93,496,391                      93,456,168 to 93,534,338                                                  93,563,564 to 93,800,894                       93,399,003 to 93,482,000                              93,412,860 to 93,923,856
  Size                                                191 kb                                        210 kb                                        78 kb                                                                     237 kb                                         83 kb                                                 511 kb
  RefSeq genes                                        *CHD2*, *ASB9P1*, *LOC100507217*, *MIR3175*   *CHD2*, *ASB9P1*, *LOC100507217*, *MIR3175*   *CHD2*                                                                    *CHD2*, *RGMA*                                 *CHD2*, *LOC100507217*, *MIR3175*                     *CHD2*, *RGMA*, *LOC100507217*, *MIR3175*
  Inheritance                                         *De novo*                                     *De novo*                                     *De novo*                                                                 *De novo*                                      *De novo*                                             *De novo*
  Development                                         Motor delay                                                                                 Communication disorder (receptive and expressive language difficulties)   Globally delayed                               Globally delayed with more significant speech delay   Unknown
  Speech delay                                                                                      Speech impairment                                                                                                                                                                                                            
                                                      Cognition                                     Learning disability                           Learning disability                                                       ID                                             ID                                                    ID
                                                      Short-term memory problems                    Short-term memory problems                                                                                                                                                                                                   
                                                      Visual perceptual disability                                                                                                                                                                                                                                               
                                                      Behaviour                                     Short attention span                          ADHD                                                                      Aggressive, impulsive, repetitive behaviours   ASD                                                   ASD
                                                      Limited social skills                         Aggressive behaviour                                                                                                                                                                                                         
                                                      Aggressive behavior                           Short attention span                                                                                                                                                                                                         
                                                      Limited social skills                                                                                                                                                                                                                                                      
  Seizure type (age of onset)                         Jeavons syndrome                              Absence seizures (3 yr)                       No epilepsy                                                               Complex partial and generalised seizures       No epilepsy                                           Unspecified seizures (2 yr)
  Absence seizures                                                                                                                                                                                                                                                                                                               
  Eyelid myoclonia (6 yr)                                                                                                                                                                                                                                                                                                        
  Brain MRI                                           Normal                                        Not done                                      Normal                                                                    Normal                                         Altered angular gyrus                                 No severe abnormalities
  Other                                               Mild hypotonia                                Mild hypotonia                                Mild hypotonia                                                            Tourette's syndrome                                                                                   
  Feeding difficulties                                Feeding difficulties                                                                        Slight hypotonia                                                                                                                                                               
  Dysmorphic features                                 Square-shaped face                            Triangular face                               Brachycephaly                                                                                                                                                                  Protruding ears
                                                      Prominent forehead                            Broad forehead                                Micrognathia                                                                                                                                                                   
                                                      High forehead                                 Short nose, upturned tip                                                                                                                                                                                                     
                                                      Full lips                                                                                                                                                                                                                                                                  
                                                      Prominent columella                           Widely spaced central maxillary incisors      Wide mouth                                                                                                                                                                     
                                                      Widely spaced teeth                                                                                                                                                                                                                                                        
  Short philtrum                                                                                                                                                                                                                                                                                                                 
  Fifth-finger brachydactyly                          Micrognathia                                                                                Prognathia                                                                                                                                                                     
  Syndactyly of toes 2 and 3                                                                                                                                                                                                                                                                                                     
  Other features                                      Mild thoracic scoliosis                       Reduced body fat mass                         Strabismus                                                                Mild thoracic scoliosis                                                                              Strabismus
  PIP joint fusion of thumbs                                                                                                                                                                                                                                                                                                     
  Mild peripheral hearing loss (higher frequencies)                                                                                                                                                                                                                                                                              
  Duplex kidney                                                                                                                                                                                                                                                                                                                  

^a^ADHD*,* Attention-deficit hyperactivity disorder; ASD, Autism spectrum disorder; Chr, Chromosome; ID, Intellectual disability; MRI, Magnetic resonance imaging; PIP, Proximal interphalangeal; RefSeq, National Center for Biotechnology Information (NCBI) Reference Sequence Database (<http://www.ncbi.nlm.nih.gov/refseq/>).

Patient 1
---------

Patient 1 has a 191-kb *de novo* deletion involving *CHD2*, the *ASB9P1* noncoding pseudogene, the uncharacterised *LOC100507217* noncoding gene and microRNA *MIR3175* (Figure [1](#F1){ref-type="fig"}). This 11-year-old girl was referred for medical genetics evaluation because she had fine and gross motor delays as well as seizures. She was born by Caesarean section at 38 weeks gestation with a birth weight of 2,977 g (25th percentile) to healthy nonconsanguineous Caucasian parents. She sat upright at age 1 year, walked at 22 months and spoke her first words at 3 years. She had learning disabilities with specific deficits in language and mathematics, and she repeated grade 3. She also had short-term memory problems, a short attention span, poor social skills and aggressive behaviour. She developed seizures at 6 years of age, which were characterised by absence seizures with eyelid myoclonia (Jeavons syndrome) and confirmed by video electroencephalogram (EEG). Her medications included lamotrigine and ethosuximide. She also had auditory neuropathy consistent with bilateral mild loss of peripheral auditory function at higher frequencies. Her physical examination revealed that she had subtle dysmorphic features, with a square-shaped face, high forehead, short philtrum, thin upper vermillion border of the lip and prominent columella. She had mild thoracic scoliosis, fusion of the proximal interphalangeal joint in both thumbs, bilateral fifth-finger brachydactyly, tapered fingers and cutaneous 2-3 syndactyly of the toes. Her neurological examination was normal, with the exception of frequent episodes of eyelid fluttering bilaterally. An MRI scan taken when she was 9 years of age was normal, as was a skeletal survey; however, an abdominal ultrasound showed a duplex right kidney. She had a normal acylcarnitine profile and normal plasma amino acids, electrolytes, lactate, urinary organic acids and FRAXA and FRAXE fragile X syndrome tests.

Patient 2
---------

Patient 2 is a 9-year-old girl who has a 210-kb deletion affecting *CHD2*, the *ASB9P1* noncoding pseudogene, the uncharacterised *LOC100507217* noncoding gene and microRNA *MIR3175* (Figure [1](#F1){ref-type="fig"}), similar to patient 1. She was referred to medical genetics for mild delays in motor and language development as well as seizures. She was born at term (41 weeks gestation) after an uneventful pregnancy to nonconsanguineous parents. Her birth weight was 3,610 g (50th percentile). She was found to have mild axial hypotonia as an infant. She first walked at age 15 months. She had feeding problems in infancy. She was diagnosed with attention-deficit/hyperactivity disorder and was being treated with dextroamphetamine and amphetamine. She showed limited social skills without any other features associated with ASD. She had visual perceptual disabilities, a communication disorder characterised by mixed receptive and expressive language difficulties and short-term memory problems. She repeated grade 1, and her performance on the Wechsler Intelligence Scale for Children--Fourth Edition was classified in the Low Average range for her age group. Absence seizures that began at 3 years of age were being treated with levetiracetam and valproic acid. Her physical examination showed that she had reduced body fat mass, a prominent forehead, a triangular face, full lips, widely spaced maxillary central incisors and micrognathia. Her neurological examination was normal. Investigations performed for the assessment of her seizures and developmental delays included G-banding karyotype, a metabolic screen including carnitine level and acylcarnitine profile, plasma amino acids, and urinary organic acids, all of which were normal. An EEG showed generalised epileptogenic dysfunction and photosensitivity. No brain imaging was performed.

Patient 3
---------

Patient 3 has a *de novo* 78-kb intragenic deletion affecting several 5′ exons of *CHD2*. No other gene was deleted in this patient. This 6-year-old girl was referred to the clinical genetics clinic for assessment of her profound delay in motor development and hypotonia. Her mother's pregnancy was unremarkable, and she was born by Caesarean section at term with a birth weight of 2,920 g (25th percentile) to healthy nonconsanguineous parents. She had feeding difficulties as an infant and had ongoing issues with chewing and swallowing food properly in early childhood. She was found to have mild hypotonia in infancy, but she had normal tone at age 6 years. She sat upright at 9 months of age and walked at 26 months. At 6 years of age, she was not able to climb stairs with alternating feet and had difficulty pedaling a tricycle. She had mild delays in her fine motor skills, and, although she had normal speech, her language comprehension skills were delayed. She scored below the first percentile on the Wechsler Preschool and Primary Scale of Intelligence--Third Edition full-scale IQ test at 4 years of age. She displayed repetitive behaviours, such as walking in circles, mouthing objects and head-banging, but she did not meet the criteria for ASD. She had a history of aggressive behaviour towards others, which has mostly resolved. She was described as having lack of insight and judgment, as well as impulsive behaviour. She had never had seizures, and her EEG and brain MRI were normal. Her medical history is significant for strabismus. Her physical examination revealed that she had normal growth parameters, including a normal head circumference. Her facial features included brachycephaly, a broad forehead with a short nose, and an upturned nasal tip. Her physical examination was otherwise unremarkable. Molecular genetic testing showed normal results for methylation-specific MLPA analysis for Prader-Willi and Angelman syndromes, *MECP2* sequencing and FRAXA fragile X syndrome testing.

Patient 4
---------

Patient 4 was found to have a 237-kb *de novo* deletion involving *CHD2* and *RGMA*. Analysis by aCGH in this 16-year-old girl was performed because of poorly controlled epilepsy as well as ASD. She is known to have very challenging behavioural issues and Tourette's syndrome. She presented in childhood with delays in motor, speech and cognition, with a more significant delay in language. At school, she exhibited difficulties in spelling and reading skills and had difficulty with mathematics. Her IQ ranged between 35 and 49. Complex partial and generalised seizures were noted between 3 and 24 months of age. Her physical examination showed that she had normal growth parameters with mild thoracic scoliosis. No striking dysmorphic features were reported. Her brain MRI was normal.

Discussion
==========

We present the clinical features of four individuals with heterozygous *de novo* deletions affecting *CHD2* who were identified from among a phenotypically heterogeneous cohort of 42,313 patients with developmental delays or ID, multiple congenital anomalies and/or ASD. The clinical symptoms of our patients are consistent with and include delays in speech and/or motor development, seizures, ID and/or learning difficulties, and neurobehavioural abnormalities, which may include autistic features, ADHD and/or aggressive behaviour. Our examination of 26,826 individuals from 13 control cohorts did not show any deletion affecting exonic sequences of this gene, indicating that deletions affecting *CHD2* are extremely rare.

Our review of the literature on *CHD2* deletions turned up one case report describing a *de novo* deletion affecting *CHD2* and *RGMA* in a patient with speech and motor delays, including ID, gait ataxia, dysmorphic features, autistic features with attention deficit, and seizures beginning at 24 months of age \[[@B9]\]. These features were attributed to haploinsufficiency of *RGMA* and/or *CHD2*. In our cohort, only one patient had a heterozygous deletion affecting *CHD2* and *RGMA*. Nevertheless, all of our patients had similar clinical findings, suggesting that *CHD2* contributes significantly to the broad spectrum of neurodevelopmental disorders and mild dysmorphic features seen in patients with *CHD2* deletions (Table [1](#T1){ref-type="table"}). In addition, in an examination of the supplemental data from genomic CNV analysis of an ASD cohort, Pinto *et al*. \[[@B10]\] reported a *de novo* deletion of *CHD2* in one patient with mild ID and ASD but no seizures \[[@B10]\]. This suggests that epilepsy may not always be present in patients with *CDH2* haploinsufficiency, as we observed in one of our four patients. In another report in the literature, Kulkarni *et al*. \[[@B27]\] described a *de novo* translocation t(X;15)(p22.2;q26.1)dn disrupting *CHD2* in a child with developmental delay, scoliosis and hirsutism. It is possible, however, that the clinical presentation of their patient may have been affected by disrupted expression of other genes near the translocation breakpoints. Interestingly, two of our patients with *CHD2* deletions had mild thoracic scoliosis, suggesting that *CHD2* disruption may predispose individuals to vertebral anomaly, as reported by Kulkarni *et al*. \[[@B27]\] and as described in the *Chd2*-mutant mouse model \[[@B5],[@B27]\]. Together, the consistent clinical features among patients diagnosed by routine clinical microarray and the *de novo* occurrence of all deletions affecting *CHD2* reported thus far support a causative role of *CHD2* haploinsufficiency for developmental delay, intellectual disability, epilepsy and behavioural problems, with phenotypic variability among individuals (Table [1](#T1){ref-type="table"}).

The results of recent studies in which researchers used massively parallel sequencing in patient cohorts investigated for epilepsy, ASD or ID provide supporting evidence for a role of *CHD2* haploinsufficiency in manifestation of the characteristics observed in our patients (Table [2](#T2){ref-type="table"}). Carvill *et al*. \[[@B11]\] performed sequence analysis of 66 candidate genes in 500 patients clinically diagnosed with epileptic encephalopathy. They found mutations predicted to be pathogenic in four patients with heterozygous *de novo* nonsense mutations and in two patients with *de novo* missense mutations disrupting the highly conserved residues in the SNF2-related helicase/ATPase domain. They described all six of their patients as having moderate to severe ID in addition to the onset of myoclonic seizures by 3 years of age. A role for *CHD2* in ID is further substantiated by a report of a *de novo* frameshift mutation identified by exome sequencing in one patient \[[@B12]\]. In another report, an exome sequencing screen carried out for *de novo* mutations in patients with infantile spasms and Lennox-Gastaut syndrome revealed one patient with a *CHD2* missense mutation \[[@B13]\]. More recently, Suls *et al*. \[[@B28]\] found three patients carrying *de novo CHD2* sequence mutations who had febrile seizures followed by therapy-resistant generalised seizures (Table [2](#T2){ref-type="table"}). In addition, they showed that a knockdown of *chd2* in zebrafish resulted in clinical and electrographic seizures \[[@B28]\]. Interestingly, none of our four patients with a deletion of *CHD2* had febrile seizures. These previous studies, together with our present case series, provide strong evidence that haploinsufficiency of *CHD2* is associated with neurodevelopmental disabilities. Despite the presence of mild dysmorphic features in most patients described thus far, no specific facial gestalt has yet been reported. In addition, no brain malformation has been visualised by MRI. Although massively parallel sequencing studies suggest a strong association between *CHD2* haploinsufficiency and seizures or ID, our study, which is based on broadly ascertained clinical cohorts, shows that such associations are not always observed. Some phenotypic variability between individuals seems to be present. Future studies will reveal whether other genetic factors influence the phenotype of this disorder or if *CHD2* haploinsufficiency is associated with other phenotypes.

###### 

**Clinical characteristics of patients with*CHD2*single-point DNA mutation**^**a**^

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Characteristics**              **Rauch*et al*.**\[[@B12]\]        **Carvill*et al*.**\[[@B11]\]      **Allen*et al*.**\[[@B13]\]              **Suls*et al*.**\[[@B28]\]                                                                                                                                                                                                                                
  ----------------------------- ---------------------------------- ------------------------------------ ----------------------------- --------------------------------------------------- ----------------------------------- ------------------------ ------------------------------ ------------------------------------------- ---------------------------------------------- -------------------------- ------------------------------------------
  Gender                                        F                                                                     M                                        F                                           F                             M                           M                                     M                                            M                                    M                                  F

  Age (yr)                                     5.75                                 17                               12                                       29                                          12                             15                         2.5                                 Unknown                                         6                                    24                                 6

  Protein change (type)          p.Thr604 Leufs\*19 (frame shift)   p.Glu1412 Glyfs\*64 (frame shift)     p.Arg121\* (frame shift)             p.Gly491 Valfs\*13 (frame shift)            p.Arg1644 Lysfs\*22 (frame shift)   p.Trp548Arg (missense)      p.Leu823Pro (missense)            c.1502+1 G\>A (splice donor)                       c.1810-2A\>C (p.?)                c.4971G\>A (p.Trp1657\*)           c.1396C\>T (p.Arg466\*)

  Inheritance                               *De novo*                           *De novo*                         *De novo*                                *De novo*                                   *De novo*                     *De novo*                   *De novo*                             *De novo*                                    *De novo*                            *De novo*                          *De novo*

  Development                            Globally delayed                       Mild delay                Normal prior to epilepsy                     Unspecified delay                      Normal before seizure onset        Unspecified delay           Unspecified delay                     Unspecified delay                         Normal prior to epilepsy             Normal prior to epilepsy        Subtle motor and speech delay

  Cognition                                  Mild ID                           Moderate ID                        Severe ID                                Severe ID                                   Severe ID                    Moderate ID                  Severe ID                              Unknown                                    Moderate ID                          Moderate ID                          Mild ID

                                            Behaviour               Uncontrolled behavioural anomalies              ASD\                                    Unknown                                     Unknown                       Unknown                     Unknown                                 ASD                                        Unknown                              Unknown                            Unknown
                                                                                                            Behavioural problems                                                                                                                                                                                                                                                                            

                                               ADHD                                                                                                                                                                                                                                                                                                                                                         

  Seizure type (age of onset)               AS (5 yr)               AtS (1 yr), AS, FS, MJ, MJ-AS, TC    MJ (1 yr), MA, NCS, TC, TS    Atypical AS (1 yr), AtS, LGS, MJ, NCS, SE, TC, TS        AtS (2 yr), MJ, SE, TC         TC (3 yr), FDS, H, MJ    MJ (2.5 yr), FDS, MJ, MA, TS   TC (6 mo), Atypical AS, AtS, FDS, LGS, MS       FS (14 mo), Atypical AS, MS, SE, TC         FS (2 yr), MA, MS, TC     TC (3.5 yr), Atypical AS, AtS, FS, H, MS

  Brain MRI                                  Unknown                             Unknown                           Unknown                                  Unknown                                     Unknown                       Unknown                     Unknown                               Normal                                        Normal                               Normal                      Nonspecific atrophy

  Other                                                                                                                                                                                                                                                                                                                                      Right hemibody weakness                     Dysarthria                              

                                              Ataxia                                                                                                                                                                                                                                                                                                                                                        

  Other features                          Duane anomaly                                                                                                                                                                                                                                                                            Language regression after corpus callosotomy                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^AS, Absence seizure; ASD, Autism spectrum disorder; AtS, Atonic seizure; FDS, Focal dyscognitive seizure; FS, Febrile seizure; H, Hemiclonic; ID, Intellectual disability; LGS, Lennox-Gastaut syndrome; MA, Myoclonic absence; MJ, Myoclonic jerk; MRI, Magnetic resonance imaging; MS, Myoclonic seizure; NCS, Nonconvulsive status; SE, Status epilepticus; TC, Tonic-clonic; TS, Tonic seizure.

Conclusions
===========

Herein we describe the first series of patients with deletions affecting *CHD2*. We provide additional evidence that deletions and pathogenic point mutations affecting *CHD2* are associated with neurodevelopmental problems, which include delays in speech and/or motor development, seizures, ID or learning difficulties, minor dysmorphic features and behaviour problems involving social difficulties and maladaptive behaviours. Although haploinsufficiency of *CHD2* is associated with a broad spectrum of neurodevelopmental disorders, we show that variability in the clinical expression of the phenotype can be observed. The overview of all currently reported mutations and their associated phenotypic features provided in this study provides a valuable resource for health-care providers caring for individuals with *CHD2* mutations.
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